Fortune, a U.S.-based multinational business magazine, has named Samsung BioLogics and Celltrion in its Future 50 list.
Fortune, in partnership with Boston Consulting Group, introduced “Future 50” category in 2017 and ranked 50 global companies with the best prospects for long-term growth. This year the two companies examined 1,100 publicly traded companies in four categories -- strategy, technology and investments, people and structure – for a year.
Among the list are multinational companies such as Netflix, Alibaba, Paypal and Alphabet.
Celltrion ranked 17th on the Future 50 list, and Samsung BioLogics ranked 47th.
Celltrion showed its excitement about its presence on the Future 50 list.
“We believe that Fortune gave a positive evaluation to our prospects for long-term growth because biosimilars we have developed are expanding sales globally and are likely to expand the U.S. market share, a market that is becoming more and more favorable to biosimilars,” a Celltrion spokesperson told Korea Biomedical Review.
Also, the expectations of the U.S. Food and Drug Administration’s approval for Truxima and Herzuma seem to have affected their positive evaluation of Celltrion’s technology, he added.
Samsung BioLogics also expressed its welcome in a press release Friday.
"Fortune Future 50 again proves Samsung BioLogics' growth potential in the global market," Samsung BioLogics CEO Kim Tae-han said. "The company will continue to make full efforts to grow into a world-leading biopharmaceutical drug developing and manufacturing company that can help our customers and patients through continuous innovation and global market development.”
<© Korea Biomedical Review, All rights reserved.>